Department of Radiation Oncology, Yonsei Liver Cancer Clinic, Yonsei University College of Medicine, Seoul, Korea.
Oncology. 2011;81 Suppl 1:123-33. doi: 10.1159/000333275. Epub 2011 Dec 22.
Although potentially curative therapies for hepatocellular carcinoma (HCC) are well established, they are offered only to a limited number of patients. For advanced HCC, sorafenib is now the treatment of choice. Radiotherapy technology has evolved remarkably during the past decade and can be precisely delivered, thereby permitting higher doses to the tumor and reduced doses to surrounding normal tissues. According to the Korean Liver Cancer Study Group (KLCSG) practice guidelines, radiation therapy is considered appropriate for unresectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B, and tumors occupying less than two thirds of the liver with level II evidence. In this review, we discuss the radiotherapeutic strategies for each clinical setting in patients with HCC.
虽然对肝细胞癌 (HCC) 的潜在治愈性疗法已得到很好的确立，但这些疗法仅提供给少数患者。对于晚期 HCC，索拉非尼是目前的首选治疗方法。放射治疗技术在过去十年中得到了显著发展，可以精确地进行治疗，从而使肿瘤接受更高的剂量，同时减少周围正常组织的剂量。根据韩国肝癌研究小组 (KLCSG) 的实践指南，对于无肝外转移、Child-Pugh 分级为 A 或 B 以及肿瘤占据不到三分之二肝脏且证据级别为 II 的不可切除、局部晚期 HCC，放射治疗被认为是合适的。在这篇综述中，我们讨论了 HCC 患者每种临床情况下的放射治疗策略。
